PKM and central nervous system cancer: The glycolysis level of glioma cells significantly decreased, whereas the apoptosis rate significantly increased; the PKM2 overexpressed glioma cells could also resist the glycolysis level changes and apoptosis changes of trametinib treatment (Figure 4F and Figure 4C).